Maternal Hemolysis After Intravenous Immunoglobulin Treatment in Fetal and Neonatal Alloimmune Thrombocytopenia
Authors:
- 1 February 2013
- journal article
- case report
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 121 (Part 2) , 471-473
Abstract
BACKGROUND: Intravenous immunoglobulin (IVIG) is a therapeutic agent used to prevent fetal thrombocytopenia in those pregnancies identified to be at risk for fetal and neonatal alloimmune thrombocytopenia. Although generally considered a safe medication, hemolytic anemia is a known side effect of IVIG treatment that may result in maternal medical complications. CASES: We present three cases of IVIG-induced maternal anemia from separate institutions that occurred during treatment for fetal and neonatal alloimmune thrombocytopenia and resolved after discontinuation or alteration of therapy. None of the treated fetuses had thrombocytopenia at birth. CONCLUSION: There is a potential for hemolysis when prescribing IVIG. We recommend laboratory monitoring for hemolytic anemia and suggest options for management including drug modification or cessation of therapy.Keywords
This publication has 7 references indexed in Scilit:
- Hematologic toxicities associated with intravenous immunoglobulin therapyInternational Immunopharmacology, 2011
- Fetal and Neonatal Alloimmune ThrombocytopeniaObstetrics & Gynecology, 2011
- Fetal and neonatal alloimmune thrombocytopenia: prenatal interventionsPrenatal Diagnosis, 2011
- Acute Hemolysis After High-Dose Intravenous Immunoglobulin Therapy in Highly HLA Sensitized PatientsClinical Journal of the American Society of Nephrology, 2009
- Intravenous immunoglobulin: Adverse reactions and managementJournal of Allergy and Clinical Immunology, 2008
- Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysisTransfusion, 2008
- Fetal Alloimmune ThrombocytopeniaNew England Journal of Medicine, 1997